potassium-3-(1,3-dioxoisoindolin-2-yl)propanoate | 1219456-88-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: potassium-3-(1,3-dioxoisoindolin-2-yl)propanoate
• 英文别名: potassium 1-phthalimidopropane-2-carboxylate；Potassium;3-(1,3-dioxoisoindol-2-yl)propanoate
• CAS: 1219456-88-8
• 化学式: C₁₁H₈NO₄*K
• 分子量: 257.287
• InChiKey: PFLJWWBBDCOOOT-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -3.57
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  77.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  potassium-3-(1,3-dioxoisoindolin-2-yl)propanoate 在 氯化亚砜 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 1,3-二氢-1,3-二氧代-2H-异吲哚-2-丙酰氯
  参考文献：
  名称：

  Synthesis and QSAR of Quinazoline Sulfonamides As Highly Potent Human Histamine H₄ Receptor Inverse Agonists

  摘要：

  Hit optimization of the class of quinazoline containing histamine H-4 receptor (H4R) ligands resulted in a sulfonamide substituted analogue with high affinity for the H4R. This moiety leads to improved physicochemical properties and is believed to probe a distinct H4R binding pocket that was previously identified using pharmacophore modeling. By introducing a variety of sulfonamide substituents, the H4R affinity was optimized. The interaction of the new ligands, in combination with a set of previously published quinazoline compounds, was described by a QSAR equation. Pharmacological studies revealed that the sulfonamide analogues have excellent H4R affinity and behave as inverse agonists at the human H4R. In vivo evaluation of the potent 2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-N-phenylethanesulfonamide (54) (pK(i) = 8.31 +/- 0.10) revealed it to have anti-inflammatory activity in an animal model of acute inflammation.

  DOI：

  10.1021/jm901379s
• 作为产物：
  描述：

  苯酐 、 β-丙氨酸 在 potassium acetate 、 溶剂黄146 作用下， 反应 2.67h， 以39%的产率得到potassium-3-(1,3-dioxoisoindolin-2-yl)propanoate
  参考文献：
  名称：

  Synthesis and QSAR of Quinazoline Sulfonamides As Highly Potent Human Histamine H₄ Receptor Inverse Agonists

  摘要：

  Hit optimization of the class of quinazoline containing histamine H-4 receptor (H4R) ligands resulted in a sulfonamide substituted analogue with high affinity for the H4R. This moiety leads to improved physicochemical properties and is believed to probe a distinct H4R binding pocket that was previously identified using pharmacophore modeling. By introducing a variety of sulfonamide substituents, the H4R affinity was optimized. The interaction of the new ligands, in combination with a set of previously published quinazoline compounds, was described by a QSAR equation. Pharmacological studies revealed that the sulfonamide analogues have excellent H4R affinity and behave as inverse agonists at the human H4R. In vivo evaluation of the potent 2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-N-phenylethanesulfonamide (54) (pK(i) = 8.31 +/- 0.10) revealed it to have anti-inflammatory activity in an animal model of acute inflammation.

  DOI：

  10.1021/jm901379s

文献信息

• [EN] CANCER TREATMENTS TARGETING CANCER STEM CELLS<br/>[FR] TRAITEMENTS ANTICANCÉREUX CIBLANT DES CELLULES SOUCHES CANCÉREUSES
  申请人：REMEDY PLAN INC

  公开号：WO2021092322A1

  公开（公告）日：2021-05-14

  Disclosed are compounds, methods, compositions, uses, and kits that allow for treating cancer. In some embodiments, the compounds are used to treat diseases or disorders. The compounds may treat cancer by targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, lymphoma, liver cancer, endometrial cancer, leukemia, or multiple myeloma. Disclosed are compounds, methods, compositions, uses, and kits that may be used in regenerative medicine. The compounds utilized in the disclosure are of Formula (0) and (I).

  本文揭示了一些化合物、方法、组合物、用途和工具包，可用于治疗癌症。在某些实施例中，这些化合物用于治疗疾病或障碍。这些化合物可能通过靶向癌症干细胞来治疗癌症。在某些实施例中，癌症可能是结直肠癌、胃癌、胃肠间质瘤、卵巢癌、肺癌、乳腺癌、胰腺癌、前列腺癌、睾丸癌、淋巴瘤、肝癌、子宫内膜癌、白血病或多发性骨髓瘤。本文还揭示了可用于再生医学的化合物、方法、组合物、用途和工具包。在本文中使用的化合物属于Formula (0)和(I)。
• Synthesis and QSAR of Quinazoline Sulfonamides As Highly Potent Human Histamine H₄ Receptor Inverse Agonists
  作者：Rogier A. Smits、Maristella Adami、Enade P. Istyastono、Obbe P. Zuiderveld、Cindy M. E. van Dam、Frans J. J. de Kanter、Aldo Jongejan、Gabriella Coruzzi、Rob Leurs、Iwan J. P. de Esch

  DOI：10.1021/jm901379s

  日期：2010.3.25

  Hit optimization of the class of quinazoline containing histamine H-4 receptor (H4R) ligands resulted in a sulfonamide substituted analogue with high affinity for the H4R. This moiety leads to improved physicochemical properties and is believed to probe a distinct H4R binding pocket that was previously identified using pharmacophore modeling. By introducing a variety of sulfonamide substituents, the H4R affinity was optimized. The interaction of the new ligands, in combination with a set of previously published quinazoline compounds, was described by a QSAR equation. Pharmacological studies revealed that the sulfonamide analogues have excellent H4R affinity and behave as inverse agonists at the human H4R. In vivo evaluation of the potent 2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-N-phenylethanesulfonamide (54) (pK(i) = 8.31 +/- 0.10) revealed it to have anti-inflammatory activity in an animal model of acute inflammation.